Company
Bristol-Myers Squibb Co
NYSE:BMY
Bristol-Myers Squibb Co is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
79 stories
Archive
US stocks close sharply higher as Biden and Trump await their fates
As of market close, Biden is seeing his lead widen in Nevada while Trump’s shrinks in Georgia and Pennsylvania
Investments and investor services
LATE MOVERS: Tesla shares slip after news of $35,000 Model 3’s launch
Also on the move are Booking Holdings, Box Inc, Bristol-Myers Squibb, Celgene, Gap, HP and Nordstrom
MORNING MOVERS: Celgene crashes as Bristol-Myers takeover thrown into doubt
Also in play in are Square Inc, Box Inc and HP Inc
Archive
EARLY MOVERS: Celgene crashes in pre-market as Bristol-Myers takeover thrown into doubt
Also in play in pre-market deals New York is Square Inc and Box Inc
Archive
EARLY MOVERS: Celgene crashes in pre-market as Bristol-Myers takeover thrown into doubt
Also in play in pre-market deals New York is Square Inc and Box Inc
Eli Lilly’s $8B bet on Loxo is a ‘vote of confidence’ for novel scientific approaches that use DNA to treat cancer
Genprex Inc CEO Rodney Varner said the deal was ‘further validation’ of the promise of cancer therapies that target specific cancer-causing genetic abnormalities
Archive
EARLY MOVERS - Loxo Oncology shares skyrocket on news of Eli Lilly acquisition; DXC Technology to buy Luxoft Holding
Also in the frame in pre-market is electric car titan Tesla and media group CBS Corp
Biotech CEOs see Bristol-Myers' $74B acquisition of Celgene as a win
The tie-up underlines how the largest pharmaceutical companies are eager to embark on the acquisition trail to boost pipelines
Sareum Holdings shares soar as Hybridan spotlights read-across from big US pharma takeover deal
The small-cap broker’s analysts noted that Bristol-Myers Squibb has agreed to acquire Celgene for US$74bn, with the combined entity to have six expected near-term product launches
EARLY MOVERS: Celgene rallies as Bristol-Myers offers to buy cancer drug company
Airline stocks decline after Delta lowered its outlook for revenue growth
Mirati Therapeutics shares tumble on release of Phase 2 trial data for lung cancer treatment
The study was evaluating Mirati’s therapy sitravatinib in combination with Bristol-Myers Squibb’s groundbreaking drug Opdivo as a method for treating non-small cell lung cancer
Bristol-Myers Squibb shares fall after FDA delays approval for lung cancer therapy
The EU is also requesting more information on overall survival rates for patients in the study
How Genprex took an abandoned pipeline drug and turned it into Oncoprex, an innovative treatment for non-small cell lung cancer
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Bristol-Myers Squibb makes $12 million investment in Compugen, sets up research partnership
New trials will evaluate the safety and tolerability of Compugen’s COM701 in combination with Bristol-Myers' immune checkpoint inhibitor Opdivo in patients with advanced cancerous tumors
EARLY MOVERS: Square shares fall and Compugen shares surge on Bristol-Myers Squibb investment as stock markets in turmoil
Also in focus before the New York bell is taxi app titan Uber and Hurricane Michael
EARLY MOVERS: Bristol-Myers Squibb shares spurt higher on FDA news, but Tesla Inc shares lose power
Also in focus in US pre-market trade was Teva Pharmaceutical Industries Ltd and Deere & Company
Merck's 2Q earnings beat Street with sales turbocharged by cancer drug Keytruda
Drug giant raised its full-year guidance to a range of US$4.22 and US$4.30 a share compared with US$4.16 to US$4.28 a share expected last quarter
Bristol-Myers Squibb's 2Q earnings beat Street on healthy sales of its blockbuster cancer drug Opdivo
The drugmaker raised its full-year forecast to between US$3.55 and US$3.65 per share, taking up the top and bottom end of its previous forecast by US$0.20 per share
PRE-MARKET MOVERS: Smartphone giant BlackBerry leaps ahead of bell after quarterly results
CarMax Inc and PayPal Holdings Inc are also stocks trending ahead of the Wall Street start..
Small-Cap Snapshot: Corindus inks deal to branch out to Japan, Funko investors file class-action suit
The medical-device company received approval to market its CorPath GRX system in Japan
Bristol Myers Squibb showcases positive results of new Phase 3 study evaluating cancer drug Opdivo
The study's results suggest Opdivo extends progression free survival in certain lung cancer patients when taken in combination with chemo and a drug called Yervoy
Jounce Therapeutics shares plunge on scant details about its Phase 1/2 ICONIC trial
The biotech's preliminary data evaluates its lead drug candidate JTX-2011
Bristol-Myers beats 1Q estimates, guides higher for full-year 2018 on drug approvals
The drug giant reported earnings of $0.94 per share on revenue of US$5.2bn. The consensus estimate from analysts was US$0.85 per share on revenue of US$5.2bn
Wall Street ends on a high as reporting season cheer continues
Wall Street shares closed Tuesday higher; The Dow Jones added over 213 points
Investments and investor services
US benchmarks close higher as earnings season points to strong growth
US stocks advanced as traders remain bullish about the corporate earnings season
Bristol-Myers falls after Citi analyst says Pfizer not interested in buying the drugmaker
New York pharma giant is also working with Harvard researchers to develop fibrotic disease treatments
Bristol-Myers Squibb’s new dosing for cancer drug Opdivo gets FDA green light
The approval is for a supplemental Biologics Licence Application which updates the Opdivo (nivolumab) dosing schedule to include 480 mg infused every four weeks
Bristol-Myers shares on the uptick after positive lung cancer trial results and market beating fourth quarter results
Its Opdivo and Yervoy cancer drug combination showed improved progression-free survival in patients with advanced lung cancer compared to chemotherapy in a Phase III trial
Bristol-Myers Squibb, Cirrus Logic, Arconic Inc, SYSCO and more - PRE-MARKET
We take a look at what's hot and what's not in pre-market deals in New York
Merck shares continue to rise after successful lung cancer trial
Results from a large-scale trial showed a combination of Merck’s Keytruda drug and an older type of chemotherapy helped newly-diagnosed cancer patients live longer and stop the disease from advancing
Bristol-Myers Squibb drops on surprise third quarter profits miss
Third quarter profits slumped to US$845mln or 51 cents per share from US$1.20bn or 72 cents a share in the year-earlier period
Halozyme Therapeutics stock to surge thanks to Bristol-Myers licensing deal
Halozyme gets US$105mln upfront plus milestone payments and a share of future revenues
Bristol Myers Squibb kidney cancer treatment meets endpoint of late-stage trial
The pharmaceutical company's combination treatment for renal cell carcinoma showed superior overall survival rates in previously untreated patients compared to chemotherapy
L Brands, Agilent Technologies, Bristol-Myers Squibb Co and more - AFTER HOURS
A first look at what happened after hours in the US market
Array Biopharma and Bristol Myers to work on colorectal cancer combo therapy
Array, MEK inhibitor, binimetinib, Bristol-Myers, immuno-oncology, Opdivo.
Bristol Myers Squibb buoyed by surge in sales of key drugs
Opdivo sales jumped by 60% in the three months to March
Bristol-Myers enters into two license deals with Biogen and Roche worth up to US$1.1bn
Bristol is licensing an experimental neurodegenerative disorder drug to Biogen and a Duchenne muscular dystrophy treatment to Roche
CytomX Therapeutics shoots higher as it's set for US$200mln upfront payment from Bristol-Myers Squibb
CytomX will also be eligible to receive up to US$448mln in milestone payments, as well as royalty payments, if development, regulatory and sales targets are met.
Exelixis to start new combo cancer trials with Bristol-Myers and Roche
Exelisis will combine Cabometyx with blockbuster PD-1 immunotherapy drug Opdivo (nivolumab)
Pharmaxis enters 2017 cashed up as shares strengthen
Pharmaxis is becoming a more enticing target for drug acquisition and partnerships.
Pharmaxis on track for multi-million euro milestone payment
The commencement of the trial will trigger a milestone payment.
US stocks trend higher, but unfazed by Trump’s damp inauguration
US stocks closed higher on Friday, but little changed following Donald Trump’s first speech as President
Bristol-Myers shares hit by new lung cancer disappointment
It made the decision about the Opdivo and Yervoy combination after assessing the data available
US shares end up as oil investors crowd out depressed pharma post-Trump speech
US shares ended higher on Wednesday, as energy investors shrugged off a jump in US oil stocks, and markets took a sanguine view of President-elect Donald Trump’s first speech since he won the November election
Bristol-Myers announces results for Opdivo
Bristol-Myers Squibb Company on Tuesday announced updated results for Opdivo monotherapy
US stocks close lower as a bonds rout indicates Dec rate hike
US stocks ended lower, swinging from initial gains amid mixed earnings results, as a global bonds sell-off ensued on growing expectations for a Dec rate hike
Broker talks up AstraZeneca's lung cancer drug prospects
Jefferies upgraded the health giant to a 'buy' recommendation
Healthy oil rise keeps markets afloat, helps energy stocks
Investors cautious on Monday following a burst of optimism
US markets ease back from record levels
A strong non-farm payrolls number eased some concerns in the market over the health of the US economy.
US shares mark record highs after NFP upside surprise
Wall Street shares marked fresh record highs on Friday after US non-farm payrolls beat consensus forecasts - by a huge margin
Records broken by S&P 500, S&P 400 and S&P 600 indexes after forecast-beating NFP
US stocks stormed higher at midsession on Friday, with the S&P 500 and mid-cap S&P 400 both chalking a fresh record high after non-farm payrolls in July hugely outstripped expectations
Bristol Myers slumps as immunotherapy drug fails lung cancer trial
The news immediately boosted shares in Merck (NYSE:MRK), which has a rival immunotherapy treatment, Keytruda.
Archive
Brokers: Jefferies warming to Baker-Hughes's strategy shift
Companies covered: Baker-Hughes, Bristol-Myers Squibb, Western Digital, GrubHub, Oshkosh, Harley Davidson, NetSuite, Pinnacle Foodsx
Bristol Myers/ Janssen target lung cancer with I-O combo
The Phase II clinical trial will evaluate the tolerability and clinical activity of the combination of two agents
Bristol-Myers Squibb to get keys to Padlock
Bristol-Myers Squibb Company is to snap up Padlock Therapeutics
Stocks find forward gear at last
The oil price (WTI) had its best day in seven years
Archive
Wall Street rallies on spate of deal-making
A flurry of M&A provided many of Monday’s highlights.
Wall Street dealmakers in rude health, stocks rally
A flurry of M&A provided many of Monday’s highlights
Wall Street to start Monday positively, traders eye M&A
Visa, Dyax, Bristol-Myers Squibb, MedAssets, Coty and TreeHouse Foods are all involved in new deals
Bristol-Myers to take over Crioxyl Pharma in $2.1bn deal
Bristol-Myers aims to to gain access to Cardioxyl's CXL-1427, a heart failure treatment.
Cancer drug firms to cash in on $9bn immunotherapy market
Trials have shown that immunotherapy may revolutionise cancer treatment
Wall Street rises as investors take positive read on mixed data; OM surges
Wall Street rose today, the first day of trade for June, as investors took a positive read on mixed second quarter economic reports. The S&P 500 (INDEXSP:.INX) rose 0.4 percent to 2,115 at 3:31 p.m. in New York. The 30-company Dow Jones